Is Hepatocyte Necrosis a Good Marker of Donor Liver Viability During Machine Perfusion?
Desley A.H. Neil, Hynek Mergental, Angus Hann, Richard W Laing, Hermien Hartog, Darius F Mirza, M. Thamara P.R. Perera – 1 September 2021
Quantification of polyreactive immunoglobulin G facilitates the diagnosis of autoimmune hepatitis
Richard Taubert, Bastian Engel, Jana Diestelhorst, Katharina L. Hupa‐Breier, Patrick Behrendt, Niklas T. Baerlecken, Kurt‐Wolfram Sühs, Maciej K. Janik, Kalliopi Zachou, Marcial Sebode, Christoph Schramm, María‐Carlota Londoño, Sarah Habes, the UK‐AIH Consortium, Ye H. Oo, Claudine Lalanne, Simon Pape, Maren Schubert, Michael Hust, Stefan Dübel, Mario Thevis, Danny Jonigk, Julia Beimdiek, Falk F. R. Buettner, Joost P. H. Drenth, Luigi Muratori, David H. Adams, Jessica K. Dyson, Amédée Renand, Isabel Graupera, Ansgar W. Lohse, George N.
Wilson’s Disease: An Analysis of Health Care Use and Cost Burden of Commercially Insured Adults in the United States
Vinod K. Rustgi, Kapil Gupta, Christopher Tait, Abhishek Bhurwal, Savan Kabaria, Carolyn Catalano, You Li, Carlos D. Minacapelli – 1 September 2021 – The economic and health care use burdens of Wilson’s disease (WD) are unknown. In this study, we aimed to quantify this health care resource use and economic burden. We performed a retrospective case‐control analysis of individuals in the Truven Health MarketScan Commercial Claims database (2007‐2017). Using propensity scores, 424 WD cases were matched 1:1 to chronic liver disease (CLD) controls without WD.
Presenting the new incoming editorial team for Hepatology: Team members and perspectives
Gregory J. Gores, Harmeet Malhi – 1 September 2021
Risk of Cardiovascular Disease in Individuals With Nonobese Nonalcoholic Fatty Liver Disease
Ashwini Arvind, Jacqueline B. Henson, Stephanie A. Osganian, Cheryl Nath, Lara M. Steinhagen, Zoe N. Memel, Arley Donovan, Oluwafemi Balogun, Raymond T. Chung, Tracey G. Simon, Kathleen E. Corey – 1 September 2021 – Nonalcoholic fatty liver disease (NAFLD) is independently associated with obesity and cardiovascular disease (CVD). CVD is the primary cause of mortality in the predominantly obese population of adults with NAFLD.
Reply: Is hepatocyte necrosis a good marker of donor liver viability during machine perfusion?
Samuel J. Kesseli, Samantha E. Halpern, Jared N. Gloria, Nader Abraham, Min Zhang, Mathew G. Hartwig, Andrew S. Barbas – 1 September 2021
Predictors of Jaundice Resolution and Survival After Endoscopic Treatment of Primary Sclerosing Cholangitis
John E. Eaton, Abdul Haseeb, Christian Rupp, Leonardo H. Eusebi, Kim Munster, Robert Voitl, Douglas Thorburn, Cyriel Y. Ponsioen, Felicity T. Enders, Bret T. Petersen, Barham K. Abu Dayyeh, Todd H. Baron, Vinay Chandrasekhara, Christopher J. Gostout, Michael J. Levy, John Martin, Andrew C. Storm, Ross Dierkhising, Patrick S. Kamath, Gregory J. Gores, Mark Topazian – 31 August 2021 – The benefit of endoscopic retrograde cholangiopancreatography (ERCP) for the treatment of primary sclerosing cholangitis (PSC) remains controversial.
Hepatic Manifestations of Urea Cycle Disorders
Alanna Strong, Jessica Gold, Nina B. Gold, Marc Yudkoff – 31 August 2021
Hepatic Manifestations of Urea Cycle Disorders
Alanna Strong, Jessica Gold, Nina B. Gold, Marc Yudkoff – 31 August 2021
Correlation Between Clinical and Pathological Findings of Liver Injury in 27 Patients With Lethal COVID‐19 Infections in Brazil
Monique Freire Santana, Mateus T. Guerra, Melanie A. Hundt, Maria M. Ciarleglio, Rebecca Augusta de Araújo Pinto, Bruna Guimarães Dutra, Mariana Simão Xavier, Marcus Vinicius Guimarães Lacerda, Anderson Jose Ferreira, David Campos Wanderley, Israel Júnior Borges do Nascimento, Roberto Ferreira de Almeida Araújo, Sérgio Veloso Brant Pinheiro, Stanley de Almeida Araújo, M. Fatima Leite, Luiz Carlos de Lima Ferreira, Michael H.